EUVIMEDEUVIMED entdecken
Crossref

Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort

A A van Zweeden, L G M van der Geest, E N Pijnappel, J de Vos-Geelen, J E van Hooft, M W J Stommel, G F de Wit, H M W Verheul, H W M van Laarhoven, H J van der Vliet, J W Wilmink, Dutch Pancreatic Cancer Group

Pancreatology · 2025

DOI: 10.1016/j.pan.2025.03.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pancreatology, 2025. Verfasst von A A van Zweeden und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; Amstelland Hospital, Department of Internal Medic…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Palliative Care, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) can improve the prognosis of advanced pancreatic ductal adenocarcinoma (PDAC). Upon progression after a therapy-free interval it is not uncommon to reintroduce FOLFIRINOX, depending on the response and progression free interval after first-line FOLFIRINOX. The aim of this study is to provide an overview of the use and effectiveness of FOLFIRINOX reintroduction in daily practice. PATIENTS AND METHODS: Patients with locally advanced and metastatic PDAC, diagnosed between 2015 and 2018, who started systemic treatment with palliative intent were selected from the Netherlands Cancer Registry (NCR). Overall and progression free survival (OS, PFS) were evaluated using Kaplan-Meier curves with log-rank tests. RESULTS: In this cohort of 2092 patients, most were treated with first-line FOLFIRINOX (1381; 66 %). The median OS was 9.0 months. A total of 388 patients (28 %) received subsequent systemic therapy after first-line FOLFIRNOX; 119 (30.7 %) patients were re-treated with FOLFIRINOX after a minimum of 3 months treatment interruption while 269 patients received other therapies, mostly gemcitabine/nab-paclitaxel or gemcitabine monotherapy. The median therapy-free interval between first-line FOLFIRINOX and FOLFIRINOX reintroduction was 7.0 months (p25-p75: 4,6-10,6). Patients underwent a median of 5 cycles (range: 1-32) during initial treatment and 5 cycles (range: 1-28) during FOLFIRINOX reintroduction. Median OS after FOLFIRINOX reintroduction was 23.4 months, and median progression-free survival was 6.8 months. CONCLUSION: Reintroduction of FOLFIRINOX after at least 3 months therapy-free interval is used in daily practice and seems a reasonable treatment option based on a favorable OS and PFS in a small subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPalliative CareCarcinoma, Pancreatic DuctalHumansLeucovorinOxaliplatinFluorouracilIrinotecanMaleFemaleMiddle AgedAgedAdultCohort StudiesAged, 80 and overNetherlands

Stichwörter der Autor:innen

Cohort studyDrug holidayFOLFIRINOXPancreatic cancerRetrospective real world data

Substanzen

LeucovorinOxaliplatinFluorouracilIrinotecanfolfirinox

Autor:innen und Institutionen

  • Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; Amstelland Hospital, Department of Internal Medicine, Amstelveen, the Netherlands.
  • Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; Netherlands Comprehensive Cancer Organization (IKNL), Department of Research and Development, Utrecht, the Netherlands.
  • Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands.
  • Div. Medical Oncology, Dept. Internal Medicine, GROW, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Leiden University Medical Center, Department of Gastroenterology and Hepatology, the Netherlands.
  • Radboud University Medical Center, Department of Surgery, Nijmegen, the Netherlands.

Zitieren

APA

van Zweeden, A. A., van der Geest, L. G. M., Pijnappel, E. N., de Vos-Geelen, J., van Hooft, J. E., Stommel, M. W. J., de Wit, G. F., Verheul, H. M. W., van Laarhoven, H. W. M., van der Vliet, H. J., Wilmink, J. W., & Dutch Pancreatic Cancer Group (2025). Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Pancreatology. https://doi.org/10.1016/j.pan.2025.03.011

Vancouver

van Zweeden AA, van der Geest LGM, Pijnappel EN, de Vos-Geelen J, van Hooft JE, Stommel MWJ, et al. Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort. Pancreatology. 2025. doi:10.1016/j.pan.2025.03.011

BibTeX
@article{vanZweeden2025,
  author = {van Zweeden, A A and van der Geest, L G M and Pijnappel, E N and de Vos-Geelen, J and van Hooft, J E and Stommel, M W J and de Wit, G F and Verheul, H M W and van Laarhoven, H W M and van der Vliet, H J and Wilmink, J W and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
  title = {Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort},
  journal = {Pancreatology},
  year = {2025},
  doi = {10.1016/j.pan.2025.03.011}
}
Kostenlos starten →